tradingkey.logo

Prothena Announces Phase 3 Affirm-Al Clinical Trial For Birtamimab In Patients With Al Amyloidosis Did Not Meet Primary Endpoint

ReutersMay 23, 2025 8:54 PM

Prothena Corporation PLC PRTA.O:

  • PROTHENA ANNOUNCES PHASE 3 AFFIRM-AL CLINICAL TRIAL FOR BIRTAMIMAB IN PATIENTS WITH AL AMYLOIDOSIS DID NOT MEET PRIMARY ENDPOINT

  • PROTHENA CORPORATION PLC - TO DISCONTINUE BIRTAMIMAB DEVELOPMENT

  • PROTHENA CORPORATION PLC - PHASE 3 AFFIRM-AL TRIAL DID NOT MEET PRIMARY ENDPOINT

  • PROTHENA CORPORATION PLC - SECONDARY ENDPOINTS NOT MET IN AFFIRM-AL TRIAL

  • PROTHENA CORPORATION PLC - BIRTAMIMAB GENERALLY SAFE AND WELL-TOLERATED

  • PROTHENA CORPORATION PLC - BOARD TO DECREASE SPEND, EXPECTS WORKFORCE REDUCTION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI